Navigating 11 Analyst Ratings For 10x Genomics
Portfolio Pulse from Benzinga Insights
Over the past three months, 11 analysts have provided diverse ratings for 10x Genomics (NASDAQ:TXG), ranging from bullish to bearish. The average 12-month price target has dropped by 35% to $26.0. Analysts have recently lowered their price targets and ratings, reflecting a cautious outlook on the company's future performance.
August 13, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have provided mixed ratings for 10x Genomics, with a significant 35% drop in the average 12-month price target to $26.0. Recent downgrades by several analysts indicate a cautious outlook on the company's future performance.
The significant drop in the average price target and the recent downgrades by multiple analysts suggest a negative short-term outlook for 10x Genomics. This indicates that analysts are cautious about the company's future performance, which could lead to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100